Abstract：Objective: To investigate the expression and correlation of caspase recruitment domain protein 9 (CARD9), pyruvate kinase M2 (PKM2), and chemokine-like superfamily member 6 (CMTM6) in breast cancer tissues. Methods: A total of 79 patients with breast cancer admitted to our hospital from November 2019 to November 2020 were selected as research objects. The expressions of CARD9, PKM2 and CMTM6 in cancer tissues and paracancerous tissues were detected by immunohistochemistry, and the expressions of CARD9, PKM2 and CMTM6 in cancer tissues and paracancerous tissues were detected by real-time fluorescence quantitative (RT-PCR). To analyze the relationship between CARD9, PKM2, CMTM6 expression and breast cancer. Results: Compared with paracancerous tissues, CARD9, PKM2 and CMTM6 expressions were higher in cancer tissues (P<0.05). With high degree of differentiation, lymph node metastasis, Ⅰ Ⅱ period compared to patients with breast cancer, low degree of differentiation, lymph node metastasis, Ⅲperiod breast cancer patients CARD9 Ⅳ, PKM2, CMTM6 had higher expression among patients of low degree of differentiation, lymph node metastasis and Ⅲ-Ⅳ period than patients of mediun-high degree of differentiation, no lymph node metastasis and I-II period (P<0.05). Correlation analysis among CARD9, PKM2 and CMTM6 showed a positive correlation between CARD9 and PKM2 (r=0.257, P=0.022). Card9 and CMTM6 were positively correlated (r=0.260, P=0.021). PKM2 and CMTM6 were positively correlated (r=0.254, P=0.024). Compared with CARD9, PKM2 and CMTM6, the combination of these three items had higher predictive value for breast cancer, with statistical difference (P<0.05). Conclusion: The facts that CARD9, PKM2, CMTM6 have abnormally high expression in breast cancer tissue and CARD9, PKM2, CMTM6 are linearly positively correlated are related with the degree of differentiation, lymph node metastasis, clinical stages, and participation in the occurrence and development of breast cancer. The three combined tests have high predictive value for breast cancer.
李玲, 何霞, 周自城, 高晓玉. CARD9 PKM2 CMTM6在乳腺癌组织中的表达及相关性研究[J]. 河北医学, 2021, 27(9): 1427-1431.
LI Ling, HE Xia, ZHOU Zicheng, et al. Expression and Correlation of CARD9 PKM2 and CMTM6 in Breast Cancer Tissues. HeBei Med, 2021, 27(9): 1427-1431.
[1] Kolak A,Kamińska M,Sygit K,et al.Primary and secondary prevention of breast cancer[J].Ann Agric Environ Med,2017,24(4):549~553. [2] Anastasiadi Z,Lianos GD,Ignatiadou E,et al.Breast cancer in young women:an overview[J].Updates Surg.2017,69(3):313~317. [3] Menta A,Fouad TM,Lucci A,et al.Inflammatory breast cancer:what to know about this unique,aggressive breast cancer[J].Surg Clin North Am,2018,98(4):787~800. [4] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J].中国癌症杂志,2019,29(8):609~679. [5] Schmidt T,van Mackelenbergh M,Wesch D,et al.Physical activity influences the immune system of breast cancer patients[J].Cancer Res Ther,2017,13(3):392~398. [6] 张宜,王健生,张玉娟,等.保乳术辅助放疗对早期乳腺癌患者的治疗效果研究[J].中国全科医学,2018,21(z1):89~90. [7] 林贵德,周春丽,何海春.胱天蛋白酶募集域蛋白9在胃癌中的表达及作用机制研究[J].中国临床研究,2016,29(2):178~181. [8] Wang T,Fan C,Yao A,et al.The adaptor protein CARD9 protects against colon cancer by restricting mycobiota-mediated expansion of myeloid-derived suppressor cells[J].Immunity,2018,49(3):504~514. [9] 常燕,唐帆,张启华,等.乳腺癌的CARD9、P12-LOX表达与钼靶X线表现相关性分析[J].中国地方病防治杂志,2017,32(11):1264~1265,1267. [10] 贺帅,刘欣媛,马俊兵,等.乳腺癌中SIRT5、PKM2及HK2的表达及其意义[J].临床与实验病理学杂志,2020,36(5):520~523. [11] 姚奥,范丽娟,黄凤,等.PKM2对乳腺癌细胞有氧糖酵解、增殖和凋亡的影响[J].生物技术,2018,28(3):273~277. [12] 丁雨,蒋敬庭.CMTM6在肺腺癌组织中的表达及其临床意义[J].中国肿瘤生物治疗杂志,2019,26(5):544~549. [13] 冯晓波,赵九洲,李武,等.PD-1、PD-L1、CMTM6在口腔鳞癌中的表达及意义[J].肿瘤学杂志,2019,25(6):577~580. [14] 杨小骏,韦俐,郑晓,等.趋化素样因子超家族6在乳腺癌组织中的表达及其与临床病理特征和预后的关系[J].中国肿瘤生物治疗杂志,2020,27(4):391~395.
2021, Vol. 27 
冀公网安备13080202000677号